2023 Cellular, Tissue, and Gene Therapies Advisory Committee
On October 31st, 2023, the U.S. Food and Drug Administration (FDA) will convene the Cellular, Tissue, and Gene Therapies Advisory Committee to discuss exagamglogene autotemcel (exa-cel), a gene therapy for the treatment of Sickle Cell Disease (SCD) for patients between the ages of 12 and 35. The Advisory Committee Meeting will be used by FDA to obtain independent expert advice on scientific, technical, and policy matters. The meeting is public and includes an opportunity for voluntary community participation through written and oral comments.
The meeting will be broadcasted live on Youtube. Click the button below to watch the meeting.